| ribavirin / Generic mfg. |
NCT00475072: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. |
|
|
| Completed | 4 | 14 | RoW | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 07/06 | 07/06 | | |
NCT00087594: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. |
|
|
| Completed | 4 | 48 | US | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 10/06 | 10/06 | | |
NCT00948220: Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 26 | Europe | peginterferon alfa-2a and ribavirin, Pegasys, Copegus | University of Ulm, Hoffmann-La Roche | Hepatitis C, Chronic, Liver Diseases, Virus Diseases | 01/07 | 03/08 | | |
| Completed | 4 | 126 | Europe | Metformine, Placebo of metformine | Valme University Hospital | Chronic Hepatitis C | | 01/07 | | |
NCT00266318: Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy |
|
|
| Completed | 4 | 40 | US | Interferon Alfacon-1 and Ribavirin | Beth Israel Medical Center, InterMune | Hepatitis C | 05/07 | 05/07 | | |
NCT00275548: Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C |
|
|
| Completed | 4 | 12 | US | Pegasys, peginterferon alfa-2a, Ro25-8310), Copegus, (ribavirin, Ro20-9963) | Mayo Clinic, Roche Pharma AG | Liver Transplant, Hepatitis C | 06/07 | 04/09 | | |
NCT00107653: Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. |
|
|
| Completed | 4 | 569 | US | Ribavirin, Peginterferon alfa-2a | Hoffmann-La Roche | Hepatitis C, Chronic | 09/07 | 09/07 | | |
NCT00001854: Long-Term Therapy With Ribavirin for Chronic Hepatitis C |
|
|
| Completed | 4 | 50 | US | Ribavirin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Hepatitis C | 10/07 | 01/08 | | |
NCT00495131: Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients |
|
|
| Completed | 4 | 308 | RoW | Pegylated interferon alfa-2a plus ribavirin, Pegasys plus Robatrol | National Taiwan University Hospital, National Science Council, Taiwan | Hepatitis C, Chronic | 06/08 | 07/08 | | |
NCT01258101: A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 |
|
|
| Completed | 4 | 395 | Europe | peginterferon alfa-2a [Pegasys], ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 07/08 | 07/08 | | |
|
PHOENIX, NCT00087633: Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. |
|
|
| Completed | 4 | 115 | US | peginterferon alfa-2a [Pegasys], Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 10/08 | 10/08 | | |
| Completed | 4 | 50 | Europe | Peginterferon alfa-2a plus ribavirin adjusted to body weight | Hospital Carlos III, Madrid | Chronic Hepatitis C, HIV Infections | 12/08 | 12/08 | | |
NCT00800748 / 2005-003932-23: A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C |
|
|
| Completed | 4 | 372 | Europe, RoW | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 01/09 | 01/09 | | |
NCT00353418 / 2005-005506-23: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection |
|
|
| Completed | 4 | 415 | US | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
NCT00394277 / 2005-005507-41: A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C |
|
|
| Completed | 4 | 1175 | US, Canada, Europe, RoW | peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
|
NCT00207311: Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus |
|
|
| Completed | 4 | 30 | US | Xenical, Pegasys, Copegus, Xenical (orlistat), Pegasys (PEG-Interferon alpha-2a), Xenicare Program, Xenical placebo, Pegasys (Peg interferon alpha-2a) | Brooke Army Medical Center, Hoffmann-La Roche, The Geneva Foundation | Fatty Liver, Hepatitis C | 05/09 | 05/09 | | |
NCT00993122: Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients |
|
|
| Completed | 4 | 100 | Europe | ribavirin pre-treatment, ribavirin pre treatment, ribavirin priming, Recurrence of hepatitis c, hepatitis c, transplanted patients, ribavirin, HCV | University of Roma La Sapienza | Hepatitis C | 04/10 | 02/12 | | |
| Completed | 4 | 167 | RoW | Pegylated Interferon alfa 2a, pegasys, Ribavirin (HIV conifected patients only) | Kirby Institute, The University of New South Wales, National Institutes of Health (NIH) | Hepatitis C | 06/10 | 06/10 | | |
NCT00686777: Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED) |
|
|
| Completed | 4 | 75 | NA | Pegylated Interferon alfa-2b, SCH 54031, Ribavirin, SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 12/10 | 12/10 | | |
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. |
|
|
| Completed | 4 | 155 | US | peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos | Hoffmann-La Roche | Hepatitis C, Chronic | 12/10 | 12/10 | | |
| Completed | 4 | 15 | Europe | Ribavirin | Maastricht University Medical Center, Roche Pharma AG | Hepatitis C | 12/12 | 12/12 | | |
NCT00977054: Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load |
|
|
| Terminated | 4 | 59 | RoW | DFPP + Peg-IFN + RBV, DFPP: Plasmaflo + Cascadeflo EC-50W (Asahi), Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche), RBV: Copegus (Hoffman La-Roche), Peg-IFN + RBV | National Taiwan University Hospital, National Science Council, Taiwan, Department of Health, Executive Yuan, R.O.C. (Taiwan) | Hepatitis C | 12/12 | 12/12 | | |
NCT01033448: A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response |
|
|
| Completed | 4 | 59 | RoW | COPEGUS, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/13 | 06/13 | | |
NCT01045278 / 2007-001130-13: Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy |
|
|
| Completed | 4 | 277 | Europe | Pegylated interferon-alfa-2b and ribavirin | Region Skane | Hepatitis C | 09/13 | 09/13 | | |
NCT01585324 / 2011-001256-10: A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) |
|
|
| Completed | 4 | 30 | Europe | peginterferon alfa-2a [Pegasys], ribavirin [Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 01/14 | 01/14 | | |
NCT00532701: Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR |
|
|
| Completed | 4 | 880 | RoW | Peg-IFN + WB RBV for 16 weeks, Pegasys plus Copegus, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks, Peg-IFN + WB RBV for 48 weeks, Peg-IFN + LD RBV for 24 weeks | National Taiwan University Hospital, National Science Council, Taiwan, Department of Health, Executive Yuan, R.O.C. (Taiwan) | Chronic Hepatitis C | 03/14 | 03/14 | | |
NCT01591460 / 2011-004810-41: A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C |
|
|
| Completed | 4 | 165 | Europe | boceprevir, peginterferon alfa-2a [Pegasys], ribavirin (Copegus] | Hoffmann-La Roche | Hepatitis C, Chronic | 06/14 | 06/14 | | |
NCT01405027: Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy |
|
|
| Completed | 4 | 197 | US | Educational Intervention, Peg-Intron, Pegasys, Victrelis, Pegylated interferon alfa 2B, Pegylated interferon alfa 2A, Boceprevir, Ribavirin, Patient education and management skills training | Chronic Liver Disease Foundation, SCRI Development Innovations, LLC, Merck Sharp & Dohme LLC | Chronic Hepatitis C, Genotype 1 | 07/14 | 07/14 | | |
|
| Completed | 4 | 82 | RoW | Peginterferon alfa-2a, Pegasys, Ribavirin | Kirby Institute | Acute Hepatitis C | 06/15 | 06/15 | | |
VALOR-HCV, NCT02128542: Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis |
|
|
| Completed | 4 | 66 | US | Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, RBV | Gilead Sciences | Hepatitis C Virus Infection | 06/15 | 06/15 | | |
NCT01686789: Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 |
|
|
| Completed | 4 | 181 | RoW | Pegylated interferon alpha-2a | King Abdulaziz Medical City | Chronic Hepatitis C Virus | 08/15 | 08/15 | | |
NCT02220868: Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study |
|
|
| Completed | 4 | 10 | US | Sofosbuvir, Ribavirin, and Stribild | Saint Michael's Medical Center | Hepatitis C Infection, HIV Infection | 08/15 | 09/15 | | |
| Completed | 4 | 14 | RoW | TPV/PEG-IFN/RBV, Telaprevir brand name: INCIVO, Ribavirin brand name: COPEGUS, PEG-IFN brand name: PEGASYS | Kirby Institute, Janssen-Cilag Ltd. | Hepatitis C, Chronic | 11/15 | 01/16 | | |
| Completed | 4 | 20 | RoW | Sofosbuvir and ribavirin, Sovaldi, Copegus | Kirby Institute | Hepatitis C | 08/17 | 12/17 | | |
NCT02304159: Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics |
|
|
| Completed | 4 | 39 | US | daclatasvir, DCV, BMS-790052, Daklinza, Sofosbuvir, Sovaldi, SOF, Ribavirin, RBV | Tarek I. Hassanein, M.D., FACP, FAG, AGAF | Hepatitis C, Cirrhosis | 08/17 | 08/17 | | |
